Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Operating Leases: 2019-2024

Historic Operating Leases for Ptc Therapeutics (PTCT) over the last 6 years, with Dec 2024 value amounting to $74.9 million.

  • Ptc Therapeutics' Operating Leases rose 10.75% to $107.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.3 million, marking a year-over-year increase of 10.75%. This contributed to the annual value of $74.9 million for FY2024, which is 23.23% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Operating Leases is $74.9 million, which was down 23.23% from $97.6 million recorded in FY2023.
  • Ptc Therapeutics' Operating Leases' 5-year high stood at $100.9 million during FY2022, with a 5-year trough of $73.6 million in FY2021.
  • Moreover, its 3-year median value for Operating Leases was $97.6 million (2023), whereas its average is $91.1 million.
  • Per our database at Business Quant, Ptc Therapeutics' Operating Leases surged by 781.56% in 2020 and then dropped by 23.23% in 2024.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Operating Leases stood at $79.5 million in 2020, then declined by 7.40% to $73.6 million in 2021, then skyrocketed by 37.00% to $100.9 million in 2022, then fell by 3.21% to $97.6 million in 2023, then declined by 23.23% to $74.9 million in 2024.